Skip to main content

Hologic Value Stock - Dividend - Research Selection

Hologic

ISIN: US4364401012 , WKN: 879100

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient\'s extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Hologic, Inc. (HOLX) Shareholder/Analyst Call - Slideshow

2026-02-06

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

2026-02-04
MARLBOROUGH, Mass., February 04, 2026--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

Robert Olstein's Strategic Moves: Exiting Hologic Inc with a -1.44% Impact

2026-02-03
Insights into Robert Olstein (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing

Hologic (HOLX) International Revenue Performance Explored

2026-02-02
Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

2026-02-02
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash

2026-01-30
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.

Blackstone Q4 Earnings Call Highlights

2026-01-30
Blackstone (NYSE:BX) executives used the firm’s fourth-quarter and full-year 2025 investor call to highlight record financial results, a sharp pickup in fundraising, and early signs of a reopening in capital markets that could support higher realizations in 2026 and beyond. Record year for distribu

Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics

2026-01-29
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates

2026-01-29
Hologic (HOLX) delivered earnings and revenue surprises of -4.46% and -2.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Hologic: Fiscal Q1 Earnings Snapshot

2026-01-29
MARLBOROUGH, Mass. AP) — Hologic Inc. HOLX) on Thursday reported fiscal first-quarter earnings of $179.1 million.